<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444442</url>
  </required_header>
  <id_info>
    <org_study_id>002/15</org_study_id>
    <nct_id>NCT02444442</nct_id>
  </id_info>
  <brief_title>Sham Controlled Clinical Trial of Renal Denervation in Patients With Resistant Hypertension</brief_title>
  <official_title>The Australian SHAM Controlled Clinical Trial of Renal DeNervation in Patients With Resistant Hypertension (AUSHAM-RDN-01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker IDI Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baker IDI Heart and Diabetes Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy catheter-based renal denervation in
      reducing blood pressure in patients with resistant hypertension compared to a sham procedure.
      Patients will be randomized to RDN or sham control in a 2:1 ratio. All participants will be
      switched to a single pill triple combination treatment prior to the procedure.

      A total of 105 patients will be recruited into the study, 70 patients in the RDN arm and 35
      patients in the sham control arm.

      The duration of this study is 36 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ambulatory systolic blood pressure between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Difference in mean ambulatory systolic daytime blood pressure between RDN group and sham-control group at 6 month follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean 24h systolic blood pressure between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Change in mean 24h systolic blood pressure between RDN group and sham-control group at 6 month follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean night time systolic blood pressure between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Change in mean night time systolic blood pressure between RDN group and sham-control group at 6 month follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean office systolic blood pressure between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Change in mean office systolic blood pressure between RDN group and sham-control group at 6 month follow up.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in percentage of patients achieving BP target between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Change in percentage of patients achieving BP target between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in percentage of patients with an ambulatory systolic BP reduction ≥5mmHg between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Change in percentage of patients with an ambulatory systolic BP reduction ≥5mmHg between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in percentage of patients with an office systolic BP reduction ≥10mmHg between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Change in percentage of patients with an office systolic BP reduction ≥10mmHg between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of sympathetic nerve activity between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Change of sympathetic nerve activity (MSNA, renal and whole body NE spillover) between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in left ventricular function between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Change in left ventricular function (LV mass index, ejection fraction, diastolic filling) between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Biochemistry between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Plasma Renin Activity, aldosterone levels, estimated Glomerular Filtration Rate(eGFR), inflammatory markers, fasting glucose, fasting insulin, C-peptide, Homeostasis Model Assessment (HOMA) index, Lipid profile between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Urine Biochemistry between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Urinary albumin creatinine ratio (UACR), 24 hour urinary creatinine clearance, sodium between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Quality of Life between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Change in Quality of life as assessed by relevant questionnaires between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in cognitive function between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Change in cognitive function as assessed by relevant questionnaires and assessment tools between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in microRNA expression between groups</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Change in microRNA expression as assessed by relevant assays between groups</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal Denervation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants randomised to undergo renal denervation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>participants randomised to undergo sham procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation</intervention_name>
    <description>Deliberate disruption of the renal nerves via radio frequency energy delivery to renal arteries.</description>
    <arm_group_label>Renal Denervation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham control</intervention_name>
    <description>Arterial access only. No delivery of radio frequency energy to renal arteries.</description>
    <arm_group_label>Sham control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  systolic BP ≥140mmHg and ambulatory day time average ≥130mmHg despite concurrent
             treatment with ≥3 anti-hypertensive drugs

        Exclusion Criteria:

          -  renal artery anatomy ineligible for treatment

          -  eGFR &lt;15mL/min/1.73m2 (using MDRD calculation)

          -  myocardial infarction, unstable angina or cerebrovascular accident within 3 months of
             screening visit

          -  life expectancy of &lt;12 months

          -  female participants of childbearing potential must have negative pregnancy test prior
             to treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus P Schlaich, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratory Head, Neurovascular Hypertension and Kidney Disease (Baker IDI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus P Schlaich, Professor</last_name>
    <phone>+61 3 85321502</phone>
    <email>Markus.Schlaich@bakeridi.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Murray Esler, Professor</last_name>
    <phone>+61 3 85321338</phone>
    <email>Murray.Esler@bakeridi.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baker IDI Heart &amp; Diabetes Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal denervation</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Cardiovascular risk</keyword>
  <keyword>Target organ damage</keyword>
  <keyword>Sympathetic activity</keyword>
  <keyword>Non-compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

